Re-Vana Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Series B
  • (Cancelled)

  • Investors
  • 11

Re-Vana General Information

Description

Developer of a biodegradable drug delivery platform designed to address ophthalmic conditions. The company's platform uses pre-formed, photo-crosslinked biodegradable implants to facilitate sustained intraocular release of active pharmaceutical ingredients and a patented system that involves the injection of a gel into the eye using a narrow gauge, enabling healthcare providers and pharmaceutical companies to save costs and patients to receive reduced pain, side effects, and treatment frequency.

Contact Information

Formerly Known As
Revana Ocular
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 63 University Road
  • Belfast BT7 1NF
  • Northern Ireland, United Kingdom
+44 028
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
Corporate Office
  • 63 University Road
  • Belfast BT7 1NF
  • Northern Ireland, United Kingdom
+44 028

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Re-Vana Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 28-Jul-2025 Cancelled Pre-Clinical Trials
8. Later Stage VC (Series A) 28-Nov-2022 Completed Pre-Clinical Trials
7. Grant 01-Jun-2022 Completed Pre-Clinical Trials
6. Later Stage VC 02-Jun-2020 Completed Pre-Clinical Trials
5. Grant 01-Jan-2019 Completed Pre-Clinical Trials
4. Seed Round 27-Nov-2017 Completed Pre-Clinical Trials
3. Grant 09-Oct-2015 Completed Pre-Clinical Trials
2. Accelerator/Incubator 28-May-2015 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2015 Completed Startup
To view Re-Vana’s complete valuation and funding history, request access »

Re-Vana Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A Preferred Ordinary
Series 1 Preferred
Ordinary
Ordinary 172,407 $0.000117 $4.16 $4.16 1x $4.16 8.22%
Preference 168,343 $0.000117 $4.16 $4.16 1x $4.16 8.03%
To view Re-Vana’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Re-Vana Patents

Re-Vana Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136552-A1 Device and methods for implant delivery Pending 18-Dec-2024
WO-2026122994-A1 Compositions for drug delivery and treatment methods Pending 06-Dec-2024
WO-2026122997-A1 Implants and compositions for drug delivery and treatment methods Pending 06-Dec-2024
AU-2021291059-A1 Biodegradable compositions and implants Pending 19-Jun-2020
CA-3183343-A1 Biodegradable compositions and implants Pending 19-Jun-2020 A61K9/0051
To view Re-Vana’s complete patent history, request access »

Re-Vana Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Re-Vana Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
ExSight Ventures Venture Capital Minority
InFocus Capital Partners Venture Capital Minority
Invest Northern Ireland Limited Partner Minority
QUBIS Venture Capital Minority
Visionary Venture Fund Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Re-Vana FAQs

  • When was Re-Vana founded?

    Re-Vana was founded in 2015.

  • Where is Re-Vana headquartered?

    Re-Vana is headquartered in Belfast, United Kingdom.

  • What is the size of Re-Vana?

    Re-Vana has 21 total employees.

  • What industry is Re-Vana in?

    Re-Vana’s primary industry is Drug Delivery.

  • Is Re-Vana a private or public company?

    Re-Vana is a Private company.

  • What is Re-Vana’s current revenue?

    The current revenue for Re-Vana is .

  • How much funding has Re-Vana raised over time?

    Re-Vana has raised $16.6M.

  • Who are Re-Vana’s investors?

    ExSight Ventures, InFocus Capital Partners, Invest Northern Ireland, QUBIS, and Visionary Venture Fund are 5 of 11 investors who have invested in Re-Vana.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process